Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Portfolio Pulse from Benzinga Insights
Deep-pocketed investors show a divided sentiment on Regeneron Pharmaceuticals (NASDAQ:REGN), with options trading indicating a price target range of $930 to $1260. The trading activity includes both bullish and bearish positions, with notable options activity highlighted. Regeneron, known for its products in eye disease, cardiovascular disease, cancer, and inflammation, has a current stock price of $966.3. Analysts have given an average target price of $1125, with mixed ratings from Bernstein, Truist Securities, and Morgan Stanley.
March 28, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals shows a mixed sentiment among investors, with options trading indicating a potential price range of $930 to $1260. Analysts provide an average target price of $1125, despite the current neutral RSI indicators.
The divided sentiment among investors, with equal bullish and bearish positions, suggests uncertainty about REGN's short-term price direction. However, the analyst ratings and the specified price target range indicate a potential for stability or slight growth, justifying a neutral score.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100